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Abstract: Pentamidine has a long
history in the treatment of human
African trypanosomiasis (HAT) and
leishmaniasis. Early guidelines on
the dosage of pentamidine were
based on the base-moiety of the
two different formulations avail-
able. Confusion on the dosage of
pentamidine arose from a different
labelling of the two available prod-
ucts, either based on the salt or
base moiety available in the prep-
aration. We provide an overview of
the various guidelines concerning
HAT and leishmaniasis over the
past decades and show the confu-
sion in the calculation of the
dosage of pentamidine in these
guidelines and the subsequent
published reports on clinical trials
and reviews. At present, only pent-
amidine isethionate is available,
but the advised dosage for HAT
and leishmaniasis is (historically)
based on the amount of pentami-
dine base. In the treatment of
leishmaniasis this is probably re-
sulting in a subtherapeutic treat-
ment. There is thus a need for a
new, more transparent and concise
guideline concerning the dosage of
pentamidine, at least in the treat-
ment of HAT and leishmaniasis.
Antiprotozoal Activity of
Pentamidine
The finding of the antiprotozoal activity
of the diamidine family of drugs was largely
a matter of serendipity. They were discov-
ered during a search for hypoglycaemic
compounds that could affect trypanosomes.
Of the compounds synthesized, pentami-
dine(Figure 1)provedto be themost useful,
andsincethe early1940sithasbeenused in
the treatment and prophylaxis of human
African trypanosomiasis (HAT, also known
as sleeping sickness) and to some extent in
the treatment of visceral leishmaniasis in
India. Nowadays, pentamidine is mainly
used for prophylaxis and treatment of
Pneumocystis jirovecii pneumonia (PCP), and
in the treatment of first-stage HAT and of
several forms of American cutaneous
leishmaniasis.
In the past, two galenic formulations,
both lyophilized salts of pentamidine (see
Box 1), were available, one the 2-hydro-
xyethanesulfonic acid salt, called pentam-
idine isethionate (Pentacarinat or Pentam),
the other the methanesulfonic acid salt,
called pentamidine methanesulfonate or
mesylate (Lomidine). These two prepara-
tions were used interchangeably, depend-
ing on local availability and preference,
until the early 1990s when production of
pentamidine methanesulfonate was
stopped and only pentamidine isethionate
remained.
Guidelines on the Treatment of
Human African
Trypanosomiasis
From the first published guidelines
onwards, the dosage of pentamidine was
expressed in and based on the active
ingredient, the pentamidine base-moiety
of the salt preparations. Pentamidine is-
ethionate contains 1 g of base per 1.74 g of
salt, while pentamidine methanesulfonate
contains 1 g of base per 1.56 g of salt. The
labelling of the ampoules of the different
products is a source of confusion; pentam-
idine isethionate is labelled according to the
amount of salt in the preparation (300 mg
salt per ampoule), while pentamidine
methanesulfonate was labelled according
to the base-moiety (120 mg base per
ampoule). The successive guidelines of the
World Health Organization (WHO) for
pentamidine in the treatment of Trypanoso-
ma brucei gambiense infection as found in the
WHO Technical Report Series demon-
strate this confusion. In the first report of
1962, one reads that ‘‘3–4 mg of base/kg of
body-weight’’ per injection should be
administered [1].
In 1969 and 1979, the two different
preparations are mentioned and it is
indicated that the salts have to be back-
calculated to the appropriate base-moiety
such that 3–4 mg of base/kg body weight
will be given [2,3]. In 1986, confusion
arose once more: again the two salts are
mentioned, and it is indicated that 4 mg
base/kg is to be administered, but the
advised dose in millilitres per injection is
based on the labelling of the different
preparations and thus for pentamidine
methanesulfonate on the base-moiety,
but for pentamidine isethionate on the
total amount of salt [4]. For pentamidine
methanesulfonate this leads to the recom-
mended dose of 4 mg base/kg per dose,
but at the recommended 2 ml of pentam-
idine isethionate salt a 50-kg person only
receives 200 mg of pentamidine isethio-
nate salt per dose, which is equivalent to
2.3 mg base/kg, while at 4 mg base/kg
348 mg of isethionate salt should be given
(1.74 mg isethionate salt=1 mg base).
After interruption of production of
pentamidine methanesulfonate, the confu-
sion remained. In Drugs Used in Parasitic
Diseases, a WHO monograph published in
1995, ‘‘4 mg/kg’’ per injection was ad-
vised without mentioning salt or base [5].
The WHO Expert Committee advised
‘‘4 mg of pentamidine isethionate per kg
body weight’’ in 1998 [6], while the
Scientific Working Group in 2003 recom-
mended ‘‘4 mg of pentamidine base per
kg’’ [7]. The latest clinical guidelines of
Me ´decins Sans Frontie `res advise an am-
biguous dosage of ‘‘4 mg/kg once daily’’
of pentamidine isethionate [8].
This confusion is also found in Man-
son’s textbook of tropical medicine. In the
16th edition of 1966, both drugs are
mentioned as salt and base and 4 mg
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1972 only mentions pentamidine isethio-
nate and advises on 4 mg/kg per injection
without mentioning salt or base [10]. This
is continued in further editions. In recent
publications on the treatment of trypano-
somiasis, pentamidine [11] and pentami-
dine isethionate [12], both at 4 mg/kg per
dose, are mentioned without indication of
base or salt. As only pentamidine isethio-
nate has been available since 1992, these
authors probably treated patients with a
relatively low dose of 2.3 mg base/kg per
dose. Whether this low dose is a subther-
apeutic dose and leads to a decrease in
efficacy and possibly also in toxicity of
pentamidine in HAT does not follow from
these studies, but obviously needs further
investigation. Indications of increased
relapse rates since the change of pentam-
idine salts are not available. However, the
lower dosage contradicts the latest WHO
Scientific Working Group recommenda-
tion, and either this recommendation
should be adjusted based on expert
opinions and experiences from the field,
or another dose should be applied [8].
Pentamidine in the Treatment
of Leishmaniasis
In the WHO Technical Report Series
pertaining to the leishmaniases, 4 mg/kg
is mentioned without indication of base or
salt [13,14]. An extensive review of the
treatment of the leishmaniases does not
mention the differences in composition
and dosing of the two preparations [15].
Differences in efficacies are described for
various types of leishmaniasis and for
various regions, but without knowing the
amount of actual product given, it
remains difficult to assess the data [15].
After interruption of the production of
pentamidine methanesulfonate, the differ-
ences between the two salts of pentami-
dine and their labelling and the resulting
difference in efficacy rates were already
noticed in the treatment of South Amer-
ican leishmaniasis [16]. In French
Guyana, cutaneous leishmaniasis caused
by Leishmania guyanensis was treated with
4 mg/kg pentamidine methanesulfonate
(thus, 4 mg pentamidine base/kg). When,
in 1992, pentamidine isethionate replaced
pentamidine methanesulfonate and was
used at the same dose of 4 mg/kg,
clinicians noticed a decreased efficacy. A
dose of 7 mg pentamidine isethionate/kg,
equivalent to 4 mg pentamidine base/kg,
restored effectiveness [16]. Also, in the
treatment of visceral leishmaniasis in
India, a difference in response to the
two pentamidine formulations was no-
ticed [17]. After the disappearance of
pentamidine methanesulfonate from the
Indian market, pentamidine isethionate
was used at the ‘‘same’’ dosage of 4 mg/
kg, and a reduction in efficacy as well as
toxicity was observed [17]. Most proba-
bly, the dosage was based on the labelling
and thus only 2.3 mg/kg base (4 mg/kg
pentamidine isethionate) was adminis-
tered. Retrospectively, the observed high-
er relapse rate and less distinct toxicity
profile in these visceral leishmaniasis
patients was not caused by a different
kind of pentamidine salt, but by an
inherent, unnoticed change of dosage.
Conclusion
There is a need for a more transparent
guideline concerning pentamidine, at least
for the treatment of HAT and leishman-
iasis. The former availability of different
salts of pentamidine and their differences
Box 1. Pentamidine Salts
Because of the instability of aqueous pentamidine solutions, pentamidine
(C19H24N4O2) is available for clinical use in the form of a powdered salt and
reconstituted with water prior to administration. Pentamidine is a weak diprotic
base due to the two amidine groups at both ends of the molecule, which means
it can accept two protons in total and thus requires two monoprotic acid
molecules to form a salt.
A few pentamidine salts are described in The Merck Index [18], which can be
formed with the following acids:
N Hydrochloric acid, forming pentamidine dihydrochloride (C19H24N4O2.2HCl),
which is not in clinical use at the moment.
N 2-Hydroxyethanesulfonic acid, forming pentamidine diisethionate
(C19H24N4O2.2C2H6O4S, Figure 1), which is most often incorrectly described as
‘‘pentamidine isethionate’’, also in The Merck Index [18].
N Methanesulfonic acid, forming pentamidine dimethanesulfonate or dimesylate
(C19H24N4O2.2CH4O3S, Figure 1), which is also confusingly named ‘‘pentamidine
methanesulfonate’’ or ‘‘pentamidine mesylate’’ in The Merck Index [18].
In accordance with most of the medical literature concerning pentamidine, the
labels of the available preparations, and for reasons of uniformity, we chose to
use the chemically incorrect names ‘‘pentamidine isethionate’’ and ‘‘pentamidine
methanesulfonate’’ to refer to the two aforementioned salts of pentamidine in
this article.
Figure 1. Structural Formulas of Pentamidine, Diisethionate, and Dimethanesulfonate.
doi:10.1371/journal.pntd.0000225.g001
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labelling of the preparation led to great
confusion in guidelines and reviews, and
reports on clinical trials. In the future, it
should clearly be stated which preparation
is used and on which moiety of the
preparation (either salt or base) the
mentioned dosage is based. Since only
pentamidine isethionate is available at the
moment and this preparation is labelled
according to the amount of salt, a scheme
involving the volume of pentamidine
isethionate solution to administer per
kilogram of body weight seems most
rational as a practical guideline for nurses
and clinical officers. This should rule out
any inconsistent dosing determining falsely
the dose–efficacy relationship and will
make future clinical trials better compara-
ble.
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